Biomerica (BMRA) Cash from Investing Activities (2010 - 2025)
Biomerica (BMRA) reported Cash from Investing Activities of -$4000.0 for Q1 2025, up 75.0% on a YoY basis from -$2285.7 in Q1 2024, and up 83.33% sequentially from -$24000.0 in Q2 2024.
Biomerica (BMRA) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Biomerica (BMRA) has 16 years of Cash from Investing Activities data on file, last reported at -$4000.0 in Q1 2025.
- For the quarter ending Q1 2025, Cash from Investing Activities rose 75.0% year-over-year to -$4000.0; the trailing twelve-month figure through May 2025 stood at -$44000.0 (up 61.74% YoY), and the FY2025 full-year result was -$37000.0, up 67.83% from the prior year.
- Cash from Investing Activities improved to -$4000.0 in Q1 2025, from -$24000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$4000.0 in Q1 2025 to a low of -$100539.0 in Q1 2021.
- A 5-year average of -$35965.4 and a median of -$24000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities slumped 231.53% in 2021 and jumped 81.25% in 2022, its largest moves.
- Tracing BMRA's Cash from Investing Activities over 5 years: stood at -$49613.0 in 2021, then jumped by 51.63% to -$24000.0 in 2022, then jumped by 50.0% to -$12000.0 in 2023, then slumped by 100.0% to -$24000.0 in 2024, then surged by 83.33% to -$4000.0 in 2025.
- Business Quant data shows BMRA's Cash from Investing Activities at -$4000.0 in Q1 2025, -$24000.0 in Q2 2024, and -$16000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.35 Bn | 175.06 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.93 Bn | 98.71 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.82 Bn | 66.37 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.03 Bn | 44.36 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.90 Bn | 25.62 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - | - |
| 9 | Koninklijke Philips | 23.96 Bn | 20.83 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Biomerica | 4.88 Mn | 3.54 Mn | -44,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2025 | -4,000.00 |
| Feb 28, 2025 | -4,000.00 |
| May 31, 2024 | -24,000.00 |
| May 31, 2024 | -24,000.00 |
| Feb 29, 2024 | -16,000.00 |
| Feb 29, 2024 | -16,000.00 |
| Nov 30, 2023 | -12,000.00 |
| Nov 30, 2023 | -12,000.00 |
| Aug 31, 2023 | -63,000.00 |
| Aug 31, 2023 | -63,000.00 |
| May 31, 2023 | -14,000.00 |
| May 31, 2023 | -14,000.00 |
| Feb 28, 2023 | -6,000.00 |
| Feb 28, 2023 | -6,000.00 |
| Nov 30, 2022 | -24,000.00 |
| Nov 30, 2022 | -24,000.00 |
| Aug 31, 2022 | -34,000.00 |
| Aug 31, 2022 | -34,000.00 |
| May 31, 2022 | -24,017.00 |
| May 31, 2022 | -24,017.00 |